DUPONT EXPECTS PROFIT DROP AS DRUG GOES OFF PATENT IN 2010

DuPont Co. will see a rapid drop in profits from hypertension drug Cozaar/Hyzaar starting in 2010, Chief Executive Officer Charles O. Holliday Jr. told analysts today. The drug, which contributed more than $675 million to DuPont's earnings last year, will go off patent in 2010, Holliday told analysts at a conference in Miami Beach, Fla., which aired on the company's Web site.
DelawareOnline